Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CETP | P11597 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2036882 | 0.89 | HPGD (0.40) | CYP2C19HPGDHDAC1HDAC2P2RX7 | |
| SCHEMBL2036091 | 0.86 | HPGD (0.42) | CYP2C19HPGDHDAC1HDAC2SMN1; SMN2 | |
| SCHEMBL2035442 | 0.82 | CYP2C19 (0.45) | CYP2C19HPGDHDAC1HDAC2P2RX7 | |
| SCHEMBL2039367 | 0.78 | HPGD (0.43) | CYP2C19HPGDSMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL2046038 | 0.76 | KMT2A (0.41) | HPGDHDAC1HDAC2SMN1; SMN2HDAC3 | |
| Hydrochloric Acid SCHEMBL2040601 | 0.69 | CYP2C19 (0.43) | CYP2C19HPGDHDAC1HDAC2P2RX7 | |
| SCHEMBL6471495 | 0.69 | CYP2C19 (0.38) | CYP2C19HPGDHDAC1HDAC2P2RX7 | |
| SCHEMBL7053519 | 0.68 | HDAC8 (0.54) | HPGDP2RX7SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL2033382 | 0.68 | CYP2C19 (0.44) | CYP2C19HPGDHDAC1HDAC2P2RX7 | |
| SCHEMBL2033385 | 0.67 | CYP2C19 (0.43) | CYP2C19HPGDHDAC1HDAC2P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9701595-B2 | Process for producing novel synthetic basestocks | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2017-07-11 | — | — | US | disclosed |
| EP-2516598-B1 | PROCESS FOR PRODUCING NOVEL SYNTHETIC BASESTOCKS | EXXONMOBIL CHEM PATENTS INC (US) | 2016-06-29 | — | — | EP | disclosed |
| US-8530712-B2 | Process for producing novel synthetic basestocks | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2013-09-10 | — | — | US | disclosed |
| US-20130131410-A1 | Process for Producing Novel Synthetic Basestocks | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2013-05-23 | — | — | US | disclosed |
| EP-2516598-A2 | PROCESS FOR PRODUCING NOVEL SYNTHETIC BASESTOCKS | Exxonmobil Chemical Patents Inc. (US) | 2012-10-31 | — | — | EP | disclosed |
| WO-2011079042-A2 | PROCESS FOR PRODUCING NOVEL SYNTHETIC BASESTOCKS | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2011-06-30 | — | — | WO | disclosed |
| US-20110160502-A1 | Process for Producing Novel Synthetic Basestocks | EXXONMOBIL CHEMICAL PATENTS INC. | 2011-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131410-A1 | Process for Producing Novel Synthetic Basestocks | PYM1, SCO2, SPIN4 | CYP2C19 4717/4885HPGD 4503/4885HDAC1 4063/4885 |
| US-20110160502-A1 | Process for Producing Novel Synthetic Basestocks | PYM1, SPIN4, SCO2 | CYP2C19 4731/4885HPGD 4535/4885HDAC1 4331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.